Amarin Corp Plc (AMRN)

[BioChica]

Steven Nissen, chief academic officer of the Heart and Vascular Institute in Cleveland, Ohio, who chaired the trial, said his team was “disappointed” with the result.

The company said the results of the trials would not affect the drug’s use in treating severe hypertriglyceridaemia.

Really? How are they going use EPANOVA to treat hypertriglyceridaemia under the threat of patent infringement.

When are they going to stop focusing on Triglycerides?